Dr. Maletic is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
108 Belfrey Dr
Greer, SC 29650Phone+1 864-877-2678Fax+1 864-848-4428
Education & Training
- Duke University HospitalFellowship, Child and Adolescent Psychiatry, 1992 - 1994
- Medical College of Wisconsin Affiliated Hospitals (Milwaukee)Residency, Psychiatry, 1988 - 1992
- University of Belgrade Faculty of MedicineClass of 1981
Certifications & Licensure
- SC State Medical License 1994 - 2025
- NC State Medical License 1992 - 1998
- WI State Medical License 1990 - 1993
- American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 1 citationsEfficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Cont...Maurizio Fava, Stephen M Stahl, Luca Pani, Sara De Martin, Andrew J Cutler
The Journal of Clinical Psychiatry. 2024-06-17 - Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents.Vladimir Maletic, Gregory W Mattingly, Jami Earnest
Expert Review of Neurotherapeutics. 2024-05-01 - 33 citationsUnderstanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder.Andrew J Cutler, Gregory W Mattingly, Vladimir Maletic
Translational Psychiatry. 2023-06-26
Journal Articles
- Diagnosing and Treating Patients With Mixed FeaturesRakesh Jain, MD, MPH; Vladimir Maletic, MD, MS; and Roger S. McIntyre, MD, FRCPC, Journal of Clinical Psychiatry, 9/2017
Press Mentions
- Treatment Considerations Across the Bipolar Depression SpectrumOctober 6th, 2022
- Evolving Management Strategies in MDD: Smarter Choices After Unsuccessful First-Line TreatmentSeptember 27th, 2022
- Low-Dose Cariprazine for MDD Linked to Reduced AnxietySeptember 21st, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: